Announced
Completed
Financials
Sources
Tags
contract research organization
Private
Majority
Completed
Acquisition
Friendly
United States
Single Bidder
Biotechnology
Cross Border
Test Inspection and Certification (TIC)
Synopsis
BioIVT, a provider of biospecimens, research models and services for drug and diagnostic development, completed the acquisition of XenoTech, a provider of products for ADME-Tox in vitro models and contract research services, from Sekisui Chemical, a plastics manufacturing company. Financial terms were not disclosed. "XenoTech has a well-established and excellent reputation for producing microsomes, subcellular fractions, and for designing and implementing ADME-Tox studies on a contract research basis. The XenoTech and BioIVT product portfolios are complementary, and when combined, will enable smarter science and accelerate medical breakthroughs that enhance and extend lives by delivering personalized biospecimen solutions to life science and diagnostic industries. We are also delighted to have this opportunity to expand our highly respected scientific team with the addition of experienced researchers from XenoTech," Dr. Richard Haigh, BioIVT CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.